039200.KQ

Oscotec Inc. [039200.KQ] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

039200.KQ Stock Summary

Top 10 Correlated Stocks

039200.KQ

In the News

039200.KQ Financial details

Company Rating
-
Market Cap
1077.13B
Income
-24.28B
Revenue
4.95B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-39.85
Forward P/E
-
PEG
24.29
P/S
147.1
P/B
7.09
P/C
-
P/FCF
-32.23
Quick Ratio
4.42
Current Ratio
4.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-638
EPS next Y
-
EPS next Q
-
EPS this Y
-16.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.53%
Revenue last 5Y
2.53%
Revenue Q/Q
-81.97%
EPS Q/Q
136.59%
-
-
-
-
SMA20
6.95%
SMA50
-0.62%
SMA100
6.84%
Inst Own
-
Inst Trans
-
ROA
-15%
ROE
-21%
ROC
-0.24%
Gross Margin
59%
Oper. Margin
-511%
Profit Margin
-371%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
18000.0-36000.0
52W High
-12.22%
52W Low
+75.56%
RSI
65.64
Rel Volume
0.49
Avg Volume
447.94K
Volume
218.3K
Perf Week
8.03%
Perf Month
9.72%
Perf Quarter
22.72%
Perf Half Y
25.4%
-
-
-
-
Beta
0.772208
-
-
Volatility
785.97%, 1127.44%
Prev Close
1.12%
Price
31600
Change
2.76%

Something similar

Top by Market Cap
ABEA.DE
LLY
META
BRK-A
V
Same Sector
CAMB.L
VYND
SAKAR.NS
CGM.PA
AZRX
Top Correlated Stocks
BVFL
CAPMAN.HE
NAS.OL
OBT
DIT
Similar Market Cap
2768.T
TIINDIA.NS
7735.T
3968.HK
2267.T

Company Profile

Healthcare Drug Manufacturers - General
  • Volume Average 447.94K
  • Market Capitalization 1077.13B
  • Employee 50
  • CEO Sung-Hee Son
  • Headquarters Seongnam-si,KR
  • IPO Date 2007-01-17
  • Website https://www.oscotec.com

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.